<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017766</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02588; pe20Khanna</org_study_id>
    <nct_id>NCT05017766</nct_id>
  </id_info>
  <brief_title>NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria</brief_title>
  <acronym>AntiResist</acronym>
  <official_title>NCCR AntiResist: Mono-center Study to Identify New Approaches to Combat Antibiotic-resistant Bacteria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an explorative, mono-center study including prospectively collected patient samples&#xD;
      from the University Hospital of Basel. It is to investigate antimicrobial resistance (AMR)&#xD;
      including three clinical manifestations of infectious diseases: urinary tract infection,&#xD;
      pneumonia and deep-seated infections. The focus is on four bacteria (E. coli, Klebsiella&#xD;
      species, S. aureus, P. aeruginosa) that are part of the high priority list of World Health&#xD;
      Organization (WHO). Residual patient samples are analysed for proteomic, metabolomic and&#xD;
      transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH)&#xD;
      analysis, flow cytometry analysis (FACS) and immunophenotyping and exploration of bacterial&#xD;
      properties.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The National Center of Competence in Research (NCCR) AntiResist aims at utilizing patient&#xD;
      samples in order to investigate the physiology of bacterial pathogens in human patients and&#xD;
      establishing a unique multidisciplinary network of clinicians, biologists, engineers,&#xD;
      chemists, computational scientists and drug developers.&#xD;
&#xD;
      The goal of this project is to elucidate the physiological properties of bacterial pathogens&#xD;
      in infected human patients in order to provide new ways of combatting superbugs. These&#xD;
      clinical data will be used to guide and benchmark development of patient-mimicking and&#xD;
      in-vitro models, accelerate the search for novel bacterial targets, antibacterial compounds&#xD;
      and non-conventional strategies.&#xD;
&#xD;
      In detail, the focus will be on three clinical manifestations of infectious diseases caused&#xD;
      by four critical bacterial pathogens belonging to WHO &quot;priority pathogens&quot; list: E. coli,&#xD;
      Klebsiella species, S. aureus and P. aeruginosa :&#xD;
&#xD;
      A) Urinary tract infection B) Pneumonia C) Deep-seated infections D) Controls for A), B) and&#xD;
      C) E) Clinical controls for A), B) and C) without obtained samples F) Analysis whether the&#xD;
      application of Art. 34 HFV (Weiterverwendung biologischen Materials und/oder&#xD;
      gesundheitsbezogener Personendaten f端r die Forschung bei fehlender Einwilligung und&#xD;
      Information) can avoid a bias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome: survival rate</measure>
    <time_frame>one time assessment at baseline</time_frame>
    <description>Survival rate (correlated to the in vitro retrieved host and bacterial data. In vitro retrieved host and bacterial data include: Proteomics, Metabolomics, FISH, Histology, PCR/Microbial genome sequencing, Microbial transcriptome, Antibiotic concentration, Timelapse studies, phenotypic characterisations, molecular typing, innate immune response characterization, Antibiotic tolerance testing, Microfluidic systems, 3-D models, Transcriptomics, Flow cytometry (FACS))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome: mortality rate</measure>
    <time_frame>one time assessment at baseline</time_frame>
    <description>Mortality rate (correlated to the in vitro retrieved host and bacterial data. In vitro retrieved host and bacterial data include: Proteomics, Metabolomics, FISH, Histology, PCR/Microbial genome sequencing, Microbial transcriptome, Antibiotic concentration, Timelapse studies, phenotypic characterisations, molecular typing, innate immune response characterization, Antibiotic tolerance testing, Microfluidic systems, 3-D models, Transcriptomics, Flow cytometry (FACS))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment response (binary: yes/ no)</measure>
    <time_frame>one time assessment at baseline</time_frame>
    <description>Treatment response (correlated to the in vitro retrieved host and bacterial data. In vitro retrieved host and bacterial data include: Proteomics, Metabolomics, FISH, Histology, PCR/Microbial genome sequencing, Microbial transcriptome, Antibiotic concentration, Timelapse studies, phenotypic characterisations, molecular typing, innate immune response characterization, Antibiotic tolerance testing, Microfluidic systems, 3-D models, Transcriptomics, Flow cytometry (FACS))</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Antimicrobial Resistance (AMR)</condition>
  <arm_group>
    <arm_group_label>A) Urinary tract infection</arm_group_label>
    <description>Processing of residual urine for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS), immunophenotyping. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties (Highly sensitive mass spectrometry, whole genome sequencing), expression of virulence factors, genomic alterations of bacterial species, metabolism, surface molecule expression, gene expression levels, cytokine levels, immune cell biology, antibiotic concentration (chromatography/mass spectrometry). Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included. First, a pilot study from randomly selected patients within each bacterial species group (n=50, each) is done.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B) Pneumonia</arm_group_label>
    <description>Processing of residual samples (tracheal secretion, bronchioalveolar lavage (BAL)) for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C) Deep-seated infections</arm_group_label>
    <description>Processing of intraoperative material residual samples for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D) Controls for A), B) and C)</arm_group_label>
    <description>Control samples result from patients with a suspected infection (infection sites A), B) or C), in which no microbiological confirmed infection has been diagnosed. Storage at biobank</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E) Clinical controls for A), B) and C) without obtained samples</arm_group_label>
    <description>For clinical controls, clinical characteristics of patients with detection of target pathogens in their routine samples (but which could not be included for sample analysis in this study) will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F) Cohort with analysis whether the application of Article (Art) 34 HFV can avoid a bias</arm_group_label>
    <description>Since part of the data and samples in this study are collected with the representative consent of the ethics committees, it is investigated whether the application of Art. 34 HFV prevents selection bias with respect to the study population. For this purpose, differences between the actual study population using Art. 34 HFV and the study population with provided research consent will be descriptively investigated in terms of the prevalence of multi-resistant germs and other available population characteristics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>analysis of antimicrobial resistance</intervention_name>
    <description>In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:&#xD;
(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored&#xD;
Deducted from the data will be:&#xD;
relevant human components and pathogen properties that are common to most patients with similar indication&#xD;
underlying regulatory networks and triggers in pathogen cells and human tissues.&#xD;
Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data.</description>
    <arm_group_label>A) Urinary tract infection</arm_group_label>
    <arm_group_label>B) Pneumonia</arm_group_label>
    <arm_group_label>C) Deep-seated infections</arm_group_label>
    <arm_group_label>D) Controls for A), B) and C)</arm_group_label>
    <arm_group_label>E) Clinical controls for A), B) and C) without obtained samples</arm_group_label>
    <arm_group_label>F) Cohort with analysis whether the application of Article (Art) 34 HFV can avoid a bias</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual samples from routinely collected material (urine, tracheal secretion in intubated&#xD;
      patients, sputum in cystic fibrosis patients, bronchoalveolar lavage fluid, blood,&#xD;
      deep-seated infectious material that is surgically removed).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient samples during routine collection at the University Hospital of Basel from November&#xD;
        2020 to approximately December 2024.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed (i) urinary tract infection, (ii) pneumonia (including&#xD;
             patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection&#xD;
             with focus pathogen:&#xD;
&#xD;
               -  E. coli&#xD;
&#xD;
               -  Klebsiella species&#xD;
&#xD;
               -  S. aureus&#xD;
&#xD;
               -  P. aeruginosa&#xD;
&#xD;
          -  Controls: no detectable bacteria in routine microbiology lab and no other infection&#xD;
             site at inclusion of the sample and follow up for 10 days, signed general consent&#xD;
&#xD;
          -  Clinical controls without obtained samples, but with confirmed (i) urinary tract&#xD;
             infection, (ii) pneumonia (including patients after lung transplantation, cystic&#xD;
             fibrosis) or (iii) deep-seated infection with focus pathogen:&#xD;
&#xD;
               -  E. coli&#xD;
&#xD;
               -  Klebsiella species&#xD;
&#xD;
               -  S. aureus&#xD;
&#xD;
               -  P. aeruginosa&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have refused research and reuse of their data/samples (e.g. general&#xD;
             consent) or any other decline (e.g. Patientenverf端gung).&#xD;
&#xD;
          -  other than one of the focus bacteria in routine microbiology lab&#xD;
&#xD;
          -  Age: &lt;18 years&#xD;
&#xD;
          -  Controls without signed general consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Khanna, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Division of Infectiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Khanna, Prof.</last_name>
    <phone>+41 61 328 73 25</phone>
    <email>nina.khanna@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Dehio, Prof.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Khanna, Prof. Dr. med.</last_name>
      <phone>+41 61 328 73 25</phone>
      <email>nina.khanna@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Richard K端hl, Dr. med.</last_name>
      <phone>+41 61 328 65 45</phone>
      <email>richard.kuehl@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Nina Khanna, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard K端hl, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrian Egli, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Dehio, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Morgenstern, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Siegemund, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daiana Stolz, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Tschudin Sutter, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bram Stieltjes, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dirk Buman, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Urs Jenal, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>National Center of Competence in Research (NCCR)</keyword>
  <keyword>Urinary tract infection (UTI)</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Deep-seated infections</keyword>
  <keyword>E. coli</keyword>
  <keyword>Klebsiella species</keyword>
  <keyword>S. aureus</keyword>
  <keyword>P. aeruginosa</keyword>
  <keyword>bacterial properties</keyword>
  <keyword>Community-acquired pneumonia (CAP)</keyword>
  <keyword>Hospital-acquired pneumonia (HAP)</keyword>
  <keyword>Ventilator-associated pneumonia (VAP)</keyword>
  <keyword>cystic fibrosis (CF)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

